6月18日 - ** 癌症治疗药物制造商 Novocure（NVCR.O）的股价在盘前交易中下跌 21.6%，报 14 美元
** 该公司针对新确诊脑肿瘤的治疗方案 (link) 未达到一项晚期临床试验的主要目标
** 公司表示，该试验未显示早期开始治疗的患者与在维持阶段开始治疗的患者相比，总生存期有所改善。
** 公司表示，试验结果表明两组患者均获得了持久的生存获益，且未观察到新的安全性信号
** 截至上一交易日收盘，该股年内累计涨幅达38%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.